INTRODUCTION
Neuroblastoma is the most common extracranial solid tumor of childhood. Current best available treatment (induction chemotherapy, surgery, radiotherapy, hematopoietic stem cell transplantation [HSCT] , and immunotherapy) cures approximately only one-half of patients with high-risk neuroblastoma 1, 2 ; this therapy is very toxic, and better treatments are needed. Although novel treatments of patients with recurrent/refractory neuroblastoma currently are being studied, the methods of evaluating efficacy vary. In early-phase clinical trials, Response Evaluation Criteria In Solid Tumors (RECIST) is the most common approach to the assessment of response; however, RECIST does not address the most frequent sites of recurrent neuroblastoma: the bone and bone marrow. 3 The International Neuroblastoma Response Criteria (INRC) include bone marrow and bone disease, 4,5 albeit these are not well quantified by INRC criteria, leading to variations in the interpretation of disease burden and potential poor correlation with the true disease state.
Between August 2002 and January 2014, the Children's Oncology Group (COG) conducted 9 phase 2 trials of novel single-agent or combination therapies on which patients with neuroblastoma were treated. RECIST criteria were applied to determine the tumor response; however, only 2 of these 9 trials (ANBL0322 and ANBL0421) met the objective response rate bar for success as prospectively defined per protocol. 6, 7 This highlights the need for additional agents to be tested in the phase 2 setting, and suggests that the assessment of progression-free survival (PFS), time to disease progression (TTP), and overall survival (OS) would provide important insights into the true effects of new agents/combinations that may not be apparent if RECIST-based evaluations are used exclusively. Longer follow-up may be necessary to observe benefit, as reflected by the endpoints of PFS, OS, and TTP.
The goals of the current study were: 1) to estimate PFS, OS, and TTP in a large cohort of patients with recurrent/refractory neuroblastoma who were treated with modern-era early-phase therapy to provide historical context; and 2) to identify factors prognostic of PFS and OS from the time of early-phase trial enrollment. PFS, OS, and TTP have been estimated from a large International Neuroblastoma Risk Groups (INRG) study of patients with neuroblastoma in first recurrence (2266 patients) 8 who were diagnosed from 1990 through 2002 (ie, they were not treated with modern-era therapy). Herein we provide more relevant, updated estimates of PFS, OS, and TTP. It was not a study objective, nor was it possible, to summarize response rates across trials; response criteria changed over time, but the definition of progressive disease did not. We suggest that the endpoints of TTP and PFS could be used to measure potential therapeutic benefit in neuroblastoma studies.
MATERIALS AND METHODS
To be eligible for analysis, patients had to be diagnosed with neuroblastoma and eligible for/enrolled on a COG phase 1 or 2 trial from November 2002 to January 2014 (when all COG frontline neuroblastoma trials included HSCT). All consecutive eligible patients were included. Only a patient's first early-phase COG trial enrollment was analyzed.
Phase 1 and Phase 2 Trial Eligibility Criteria
Inclusion criteria for the trials were refractory (nonresponsive) or recurrent/progressing neuroblastoma (histologically verified or present in the bone marrow with elevated urinary catecholamines at the time of diagnosis), no known standard therapy, a Karnofsky performance status-50%, 30 days since the last dose of the investigational drug/immunotherapy was administered, 21 days since last myelosuppressive therapy, 7 days since last biologic therapy, full recovery from the toxicity of prior therapy, and adequate organ function. In all but one study (ANBL0421), there were no limitations regarding the number of prior recurrences or prior therapeutic regimens. Patients who were pregnant or breastfeeding were excluded. Furthermore, in 6 phase 2 trials conducted after 2005, patients were stratified by disease that was: 1) measureable by computed tomography or magnetic resonance imaging scans or 2) evaluable, as assessed by I-123 metaiodobenzylguanidine (MIBG) scintigraphy. Patients or parents/guardians provided informed consent for trial enrollment, and trials were approved by either the local institution's Institutional Review Board or the National Cancer Institute's Pediatric Central Institutional Review Board.
Phase 1 and Phase 2 Trial Therapy
A total of 35 COG trials were included: 23 phase 1 studies, 3 phase 1/2 studies, and 9 phase 2 studies (Table 1 ) (see Supporting Information Table 1 ). The number of agents per trial were a single agent in 24 studies, 2 agents in 7 studies, 3 agents in 3 studies, and 4 agents in 1 study. The number of trials by type of treatment were singleagent cytotoxic treatment in 5 studies, 2 agents including a cytotoxic therapy in 9 studies, single-agent targeted therapy in 14 studies, 2-agent targeted therapy in 2 studies, retinoids in 2 studies, and immunotherapy in 3 studies. The planned time to first assessment of response was a median of 28 days from enrollment (range, 21-63 days) ( Table 1) .
Prior Therapy and Risk Factors at the Time of Diagnosis
Prior therapy was known only if the patient was previously treated on a COG trial (ie, unknown if prior therapy was administered "as per" COG protocols, or on trials from other groups/consortia). Risk factor data and time from diagnosis to first disease recurrence/progression (TTFR) were unknown if the patient did not enroll on a COG frontline trial or biology study.
Statistical Analysis
Analyses were conducted as intent-to-treat analyses. Time to progression for PFS and TTP were calculated from the time of early-phase trial enrollment until the first occurrence of neuroblastoma recurrence, progression, or death (Fig. 1) . For PFS, observations were censored if none of these events occurred. OS was calculated from the time of early-phase trial enrollment until death from any cause, or censored at last contact.
Kaplan-Meier curves, with standard errors according to Peto et al, were generated, 9, 10 and risk factor subgroups were compared with a log-rank test. The proportional hazards (PH) assumption was investigated, and a Cox PH regression model (backwards selection) was used to identify prognostic factors 11 using dummy variables for the "missing" category to avoid loss of sample size due to missingness. Using factors previously validated as prognostic of outcome in patients with newly diagnosed neuroblastoma, we tested them for prognostic ability in patients with recurrent/refractory disease from the time of first early-phase trial enrollment: COG risk group ( 24, 25 prior transplantation (yes vs no), and TTFR. 8, 26 To facilitate the clinical usefulness of TTFR, Table 3 for a list of the study chairs. b This is the subset of patients enrolled on the trial who met the eligibility criteria for the current analysis.
an "optimal" TTFR cutoff value was sought. Patients were randomly allocated to separate test and validation sets. Recursive partitioning was performed using a Cox model for OS to test cutoff values at 12, 15, 18, 21, 24, 27, 30, 33, and 36 months. The cutoff value with the largest hazard ratio (HR) (reference level: TTFR above the cutoff) among those with a significant P value was selected from the test set to be confirmed in the validation set.
RESULTS

Prior Therapy
Before enrolling on a COG early-phase trial, 98 of 383 patients (26%) received therapy on COG frontline trials (Table 2) . Outcomes for patients who did versus did not enroll on a COG frontline trial or biology study were similar (P 5 .8 for PFS and P 5 .3 for OS). A total of 180 of 281 patients (64%) underwent at least 1 transplantation. A total of 51 of 383 patients (13.2%) received an anti-GD2 antibody on a COG trial: dinutuximab as postconsolidation therapy in 44 patients, 27 dinutuximab for recurrent/refractory disease in 2 patients, and hu14.18-IL-2 fusion molecule in 10 patients.
Patient Characteristics
Within the subsets of patients with known risk factor data at the time of initial diagnosis, 214 of 233 patients (92%) were high risk, 205 of 234 patients (88%) had INSS stage 4 disease, 218 of 235 patients (93%) were aged 18 months at the time of diagnosis, 32 of 195 patients (16%) had tumors with MYCN amplification, 91 of 182 patients (50%) had tumors that were diploid, 165 of 177 patients (93%) had an unfavorable International Neuroblastoma Pathology Classification, 29 of 124 patients (23%) had a high mitosis-karyorrhexis index, 14 of 140 patients (10%) had differentiating grade, 14 of 31 patients (45%) had 11q LOH, and 8 of 32 patients (25%) had 1p LOH (Table 3) .
Outcome
From the time of diagnosis, the median TTFR was 18.7 months (range, 44 days to 5.4 years) among 176 patients with known TTFR. The majority of patients (117 of 176 patients; 66%) enrolled on their first COG early-phase trial > 30 days after first disease recurrence. From the time of early-phase trial enrollment, the 1-year PFS and OS rates ( 6 the standard error) were 21% 6 2% and 57% 6 3%, respectively, and the PFS and OS rates at 4 years were 6% 6 1% and 20% 6 2%, respectively (383 patients) ( Fig. 2A) (Table 3) . From the time of earlyphase trial enrollment, the median TTP was 58 days (interquartile range, 31-183 days; 350 disease recurrences) (Fig. 2B) . The median follow-up was 25.3 months (range, 0.1-145 months) in 33 patients without an event.
Prognostic Factors
Univariate analyses
Factors found to be prognostic of worse PFS were MYCN amplification (P 5 .003) and 11q LOH (P 5 .02), and those found to be prognostic of worse OS were era (P 5 .008), MYCN amplification (P<.0001), and 11q (Table 3 ). An optimal TTFR cutoff value found to be prognostic of OS could not be identified in either the test set (88 patients) or the overall cohort (176 patients) with known TTFR (see Supporting Information Table 2 ). Using a TTFR cutoff of 30 months from diagnosis to first disease recurrence, the TTFR was not found to be prognostic of PFS (P 5 .3) or OS (P 5 .055). The PH assumption was not violated for any factors.
Multivariable analysis
In multivariable analysis, MYCN and 11q were found to be independently prognostic of PFS and OS (P<.0001 and P 5 .001, respectively, and P 5 .02 and P 5 .01, respectively; 195 patients) ( Table 4) .
DISCUSSION
Herein, we report the outcome of a historical cohort of patients with recurrent/refractory neuroblastoma that is representative of patients currently enrolled onto earlyphase clinical trials in North America. A patient's first enrollment on an early-phase COG trial from November 2002 to January 2014 was included. The eligibility criteria of the trials were fairly inclusive, and were similar to currently enrolling COG and non-COG early-phase trials. The percentages of patients by prognostic factors at the time of diagnosis were as anticipated. Therefore, it is possible to use the PFS and TTP results of the current study as historical context when designing future trials of antitumor agents. OS is an objective ("hard") endpoint, but its ability to measure the treatment of interest is limited ("diluted") by additional therapy received after the treatment of interest. PFS and TTP are able to measure the treatment effect of interest without the diluting effect of intervening treatments.
In the absence of clinical symptoms, the more frequently that assessments of disease burden are performed, the sooner disease recurrence/progression can be identified. Kushner et al demonstrated the superiority of I-123 MIBG for detecting disease recurrence in routine (every 2 months to 4 months) monitoring of high-risk patients. 28 In early-phase trials, the times to disease recurrence/progression may artificially cluster around the times that disease assessments typically are performed or are dictated by the protocol. In the current study, many patients developed disease recurrence/progression within a short period of time (median TTP, 58 days) (Fig. 2B) . A limitation of the current study, and a reality of clinical care, is that disease recurrence/progression is likely observed at the times of designated disease assessments between courses (eg, 21-28 days or 42-56 days) rather than the true (earlier) time of disease recurrence/progression, resulting in variability in PFS and TTP measurements. Future meta-analyses would be aided by having more uniform timing of disease assessments across trials. Another limitation of the current study is that, due to a lack of clear protocol definitions of Abbreviations: ABMT, autologous bone marrow transplantation; BMT, bone marrow transplantation; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL-2, interleukin 2; JAK, Janus kinase; PBSC, peripheral blood stem cell; TBI, total body irradiation. "refractory," we were unable to discriminate the patients with refractory from those with recurrent/progressing disease. To address these issues, a National Cancer Institutefunded international collaboration has developed standard definitions for refractory disease and recommended time points for disease assessment. 29 A limitation of this historical cohort is a potential selection bias in terms of a disease burden that is slightly lower than the population of patients with recurrent/ refractory neuroblastoma. Patients must have been well enough to meet eligibility criteria or travel to a referral institution. This historical cohort appears to be representative of patients with recurrent disease who enrolled on early-phase trials between 2002 and 2014.
A limitation of the current study is that prior therapy and baseline risk factor data were not available unless the patient had enrolled on a COG frontline protocol. However, this did not hinder estimation of PFS, TTP, and OS. The outcome for patients with missing data was similar to that of patients who had enrolled on a frontline COG study, suggesting there was no bias. In addition, despite the reduced sample size in the current study, there was sufficient power to identify factors prognostic of PFS and OS. For the 44% of patients with data regarding known risk factors (Table 3 ) and prior treatment (Table 2) , the majority had been classified by COG as being at high risk at the time of diagnosis. It is reasonable to assume the remaining patients also were high risk, with the exception of a few patients who developed metastatic disease progression after the initial diagnosis of non-high-risk neuroblastoma. Patients with non-high-risk neuroblastoma who developed nonmetastatic disease recurrence were not eligible for the trials in the current study because they have available curative options. Among patients with known prior therapy, approximately two-thirds underwent at least 1 transplantation, which was slightly lower than anticipated. Fewer patients in the current study (13.2%) received dinutuximab than expected in future cohorts of patients with recurrent/ refractory disease because the majority of our historical cohort received frontline therapy before the efficacy of dinutuximab was identified in 2009. 27 Since 2009, the majority of high-risk patients treated in North America have received dinutuximab. The outcome for patients treated with dinutuximab who experience disease recurrence/progression should be tested in a prospective fashion in a larger anti-GD2 antibody-treated cohort.
In a large INRG study of patients with neuroblastoma in first recurrence (2266 patients), London et al demonstrated that many risk factors prognostic of OS from the time of diagnosis 30 remain prognostic of OS after disease recurrence: age, INSS stage, MYCN status, and TTFR (optimal cutoff: 30 months). 8, 26 However, in the current study, we were unable to identify an optimal TTFR cutoff value. Using a 30-month cutoff, the approximately 24% difference in the 1-year OS rate was considered clinically significant, but the sample size was too small for sufficient power to detect this difference. The difference of approximately 6% in the 1-year PFS rate for TTFR (<30 months vs 30 months) was not considered clinically significant. The INRG study included the subset of newly diagnosed patients who developed disease recurrence/progression, in contrast to the present COG cohort, which was comprised of patients in first, second, or subsequent recurrence who survived long enough and were considered well enough to enroll on a recurrence trial. The INRG and COG cohorts differ in other ways, perhaps influencing the results: 1) therapeutic differences over time (COG [2002 (COG [ -2014 had more modern treatment options for patients with recurrent disease than INRG [1990 INRG [ -2002 ); 2) therapeutic differences between countries (11 countries for INRG whereas COG was primarily North America); 3) sample size (2266 patients in INRG vs 383 in COG); and, 4) a higher percentage of high-risk patients in the COG cohort. Importantly, both the INRG and COG analyses identify MYCN status as being independently prognostic of OS after disease recurrence. Garaventa et al identified age 18 months, higher stage of disease, elevated lactate dehydrogenase, amplified MYCN, and an abdominal primary tumor as being prognostic of worse OS after first disease recurrence/progression. 31 In a large study of patients who survived >5 years after diagnosis, Cotterill et al identified age >1 year with stage 4 disease and prior disease recurrence as being prognostic of subsequent disease recurrence/ progression. 32 In this COG study, approximately 66% of patients took > 30 days after first disease recurrence to enroll on their first COG early-phase study, suggesting some received non-COG study therapy after their first recurrence. In a retrospective single-institution study, Lau et al demonstrated that shorter TTFR was prognostic of worse OS. Despite salvage regimens that were effective in extending OS, the ultimate outcome remained dismal. 33 Similarly, the outcomes for the patient cohort with recurrent/refractory neuroblastoma in the current study remained dismal (4-year PFS and OS rates of 6% 6 1% and 20% 6 2, respectively) ( Fig. 2A) , thereby highlighting the importance of continued clinical trials aimed at identifying improved therapies for these patients.
The randomized phase 2 trial remains the ideal approach for evaluating the efficacy of a new agent. The results of the current study support stratification by MYCN status, and possibly also 11q status (the Abbreviations: 95% CI, 95% confidence interval; HR, hazard ratio; LOH, loss of heterozygosity; OS, overall survival; PFS, progression-free survival. a Patients for whom both factors were unknown were excluded. b "Era" was tested in the OS model but was not found to be statistically significant. prognostic value of 11q status in patients with recurrent neuroblastoma should be confirmed in a larger cohort). Barring a randomized trial, a single-arm trial could test the superiority of a new agent compared with an efficacy "bar" (eg, 2-year PFS > 11%) selected based on the curves from the current study. However, historical controls are limited by differences in frontline therapy, supportive care, and approaches to disease assessments, and may not be representative of the outcome of patients who receive modern-era treatment. This limitation is evidenced herein by the superior outcome of patients enrolled after May 2009 compared with those enrolled before that date. Despite the limitations of historical controls, for a rare disease such as neuroblastoma, there may be situations in which this is a reasonable study design with which to identify agents that warrant further investigation.
PFS in Recurrent Neuroblastoma
The current study used a representative historical cohort of patients with recurrent/refractory neuroblastoma who were enrolled on recent COG early-phase trials to identify post-recurrence prognostic factors and establish a historical context for PFS and TTP. To the best of our knowledge, the current study is the first meta-analysis of these outcomes within the context of modern therapy. In some cases, response alone may not reflect the efficacy of a given agent for patients with neuroblastoma. Randomized phase 2 trials can be stratified by post-recurrence prognostic factors such as MYCN amplification, and use INRC response together with PFS or TTP as endpoints, in which the choice of endpoint(s) depends on a given trial's objectives and therapies. These data also indicate that the outcome for children with recurrent/progressive neuroblastoma remains dismal, thereby emphasizing the importance of developing more effective agents for this population.
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